| Reason for the Action |
Medtronic is recalling specific lots of the Abre Venous Self-Expanding Stent System, hereafter referred to as Abre. These specific lots may contain a subset of stents with a smaller-than-expected stent diameter once deployed.
Based on internal testing, if a stent is impacted, its inner diameter once deployed averages 0.5 – 0.6mm below historical Abre stents and approximately the same amount smaller than its labelling would indicate. Because of the reduced stent diameter, the associated radial force of the stent will also be reduced by a corresponding amount; other physical stent properties are unaffected by this issue.
Although all venous stents pose a risk of migration, an affected lot of Abre stent poses a potentially increased risk that the stent may migrate to the vena cava or right heart/pulmonary vasculature. While none of these harms have been clinically observed with the impacted units, migration can potentially lead to vessel occlusion, thrombus formation, vessel damage, embolism, cardiac arrhythmia and/or the need for surgical intervention, including open surgical or endovascular retrieval from the heart. Medtronic’s investigation concluded that the potential risk of serious adverse health consequences or death due to this issue is low.
As of Nov. 18, 2025, no reports of patient harm or field complaints have been received by Medtronic associated with this issue. |
| Instructions for Customers/Users |
Recall: • Immediately locate and quarantine all affected and unused Abre devices as listed in the provided scope. • Return all unused affected products in your inventory to Medtronic.
Product Alert: For patients who have received an Abre stent from an affected lot, Medtronic, in consultation with an independent physician panel, recommends that treating physicians consider individual patient anatomical variables along with IFU guidance. The risk of experiencing a migration from a stent within the affected lots is estimated at less than 2%. In consultation with an independent physician panel, Medtronic recommends obtaining baseline imaging (in accordance with local surveillance protocols) if imaging was not performed at one-month post-procedure. Understanding that individual patient circumstances vary, imaging should ultimately be performed at the discretion of the treating physician. The risk of venous stent migration lessens over time with migrations most concentrated within the first month after implant. |